Table 2.
Effect of beta-2 glycoprotein I (β2GPI) co-factor on assay-specific diagnostic performance (APS) and assay-specific diagnostic performance (RPL).
| Assay | Sensitivity (95% CI), % | Specificity (95% CI), % | ||
|---|---|---|---|---|
| + β2GPI | − β2GPI | + β2GPI | − β2GPI | |
| (a) APS | ||||
| aPA-IgM | 29·0 (18·2–42) | 16·2 (8·0–27·6) | 100·0 (95·2–100·0) | 100·0 (95·2–100·0) |
| aPC-IgM | 6·4 (1·8–15·8) | 1·6 (0·0–8·6) | 100·0 (95·2–100·0) | 100·0 (95·2–100·0) |
| aPE-IgM | 17·8 (9·2–29·6) | 13·0 (5·8–23·8) | 100·0 (95·2–100·0) | 98·6 (92·6–100·0) |
| aPG-IgM | 32·2 (21–45·4) | 4·8 (1–13·4) | 97·2 (90·6–99·6) | 100·0 (95·2–100·0) |
| aPI-IgM | 21·0 (11·6–33·2) | 16·2 (8–27·6) | 100·0 (95·2–100·0) | 100·0 (95·2–100·0) |
| aPS-IgM | 38·8 (26·6–52) | 22·6 (13–35) | 100·0 (95·2–100·0) | 100·0 (95·2–100·0) |
| aPA-IgG | 80·6 (68·6–89·6) | 74·2 (61·6–84·4) | 77·0 (65·8–86·0) | 86·4 (76·6–93·4) |
| aPC-IgG | 66·2 (53–77·6) | 3·2 (0·4–11·2) | 98·6 (92·6–100·0) | 100·0 (95·2–100·0) |
| aPE-IgG | 56·4 (43·2–69) | 35·4 (23·8–48·6) | 97·2 (90·6–99·6) | 96·0 (88·6–99·2) |
| aPG-IgG | 85·4 (74·2–93·2) | 85·4 (74·2–93·2) | 94·6 (86·8–98·6) | 86·4 (76·6–93·4) |
| aPI-IgG | 74·2 (61·6–84·4) | 61·2 (48–73·4) | 98·6 (92·6–100·0) | 98·6 (92·6–100·0) |
| aPS-IgG | 64·6 (51·4–76·2) | 83·8 (72·4–92)* | 100·0 (95·2–100·0) | 75·6 (64·4–85)* |
| (b) RPL | ||||
| aPA-IgM | 0·0 (0·0–5·4) | 0·0 (0·0–5·4) | 100·0 (95·2–100·0) | 100·0 (95·2–100·0) |
| aPC-IgM | 0·0 (0·0–5·4) | 0·0 (0·0–5·4) | 100·0 (95·2–100·0) | 100·0 (95·2–100·0) |
| aPE-IgM | 1·6 (0–8·2) | 3 (0·4–10·6) | 100·0 (95·2–100·0) | 98·6 (92·6–100·0) |
| aPG-IgM | 4·6 (1–12·8) | 0·0 (0·0–5·4) | 97·2 (90·6–99·6) | 100·0 (95·2–100·0) |
| aPI-IgM | 0·0 (0·0–5·4) | 0·0 (0·0–5·4) | 100·0 (95·2–100·0) | 100·0 (95·2–100·0) |
| aPS-IgM | 1·6 (0–8·2) | 0·0 (0·0–5·4) | 100·0 (95·2–100·0) | 100·0 (95·2–100·0) |
| aPA-IgG | 1·6 (0–8·2) | 0·0 (0·0–5·4) | 77·0 (65·8–86·0) | 86·4 (76·6–93·4) |
| aPC-IgG | 4·6 (1–12·8) | 1·6 (0–8·2) | 98·6 (92·6–100·0) | 100·0 (95·2–100·0) |
| aPE-IgG | 6·0 (1·6–14·8) | 9·0 (3·4–18·8) | 97·2 (90·6–99·6) | 96·0 (88·6–99·2) |
| aPG-IgG | 10·6 (4·4–20·6) | 0·0 (0·0–5·4) | 94·6 (86·8–98·6) | 86·4 (76·6–93·4) |
| aPI-IgG | 6·0 (1·6–14·8) | 1·6 (0·0–8·2) | 98·6 (92·6–100·0) | 98·6 (92·6–100·0) |
| aPS-IgG | 0·0 (0·0–5·4) | 25·8 (15·8–38·0)* | 100·0 (95·2–100·0) | 75·6 (64·4–85)* |
95% CI, 95% confidence interval for the calculated sensitivities and specificities for each of the indicated antibody marker in the presence (+) and absence (−) of β2GPI.
*
Denotes significant difference between assays at P < 0·05. Results for APS and RPL groups are shown using control data from the healty blood donor (HBD) and women with histories of successful pregnancies (WSP) groups. aPA, anti-phosphatidic acid; aPC, anti-phosphatidyl choline; aPE, anti-phosphatidyl ethanolamine; aPG, anti-phosphatidyl glycerol; aPI, anti-phosphatidyl inositol; aPS, anti-phosphatidyl serine; Ig, immunoglobulin.